The present invention relates generally to the field of cancer therapy. More specifically the present invention relates a combination therapy where IGF-1R antagonists are combined with MAPK/ERK pathway inhibitors. The present invention relates to a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, and to methods for the production of an anti-cancer effect in a patient. The present invention relates to: a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor a combination product comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, a kit of parts comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor use of a therapeutic combination, combination product or kit of parts in the treatment of cancer a method of treating cancer comprising administering the therapeutic combination, combination product or kit of parts to a patient.
